Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Biogenesis of lysosomal organelles complex 3 subunit 2 (HPS4) is a protein that forms a stable heterodimeric complex with HPS1, known as the BLOC-3 complex[1][2]. This complex is involved in the trafficking and biogenesis of lysosome-related organelles, including melanosomes in pigment cells and platelet dense granules. BLOC-3 acts as a guanine nucleotide exchange factor (GEF) for the small GTPases RAB32 and RAB38 and is an effector of RAB9A, thereby regulating essential processes in vesicle trafficking and organelle function[1]. Mutations in HPS4 disrupt this complex and lead to Hermansky-Pudlak syndrome type 4, a rare autosomal recessive disorder characterized by albinism, bleeding diathesis, and, in some subtypes, fatal pulmonary fibrosis[1][2]. HPS4 itself is not classically considered a direct therapeutic drug target such as a receptor or enzyme, but pathogenic variants in HPS4 are clinically relevant for diagnosis and disease understanding in the context of lysosome-related organelle diseases[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Biogenesis of lysosomal organelles complex 3 subunit 2 (HPS4).